overall

Guardant Health to Share Data Supporting Critical Role of Blood-Based Testing in Improving Cancer Screening Adherence at ACG 2025

Expanded cohort reiterates strong adherence rate of over 90% for Shield blood-based colorectal cancer screening test Survey findings show eligible…

2 weeks ago

Manipal Hospital Sarjapur Road Empowers Fitness Enthusiasts with CPR Skills and First-Aid Workshop

BENGALURU, India, Oct. 14, 2025 /PRNewswire/ -- With the growing emphasis on fitness and overall well-being, fitness enthusiasts do much…

2 weeks ago

Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumour shrinkage was observed in 82 percent of patients1 New findings from this investigational…

3 weeks ago

PSMAddition data show Novartis Pluvicto delays progression to end-stage prostate cancer

Basel, October 19, 2025 – Novartis today presents new Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) data from the Phase III PSMAddition…

3 weeks ago

Lamborghini SC63 finishes fourth in IMSA seasonending Petit Le Mans

Mortara-Kvyat-Grosjean fight for overall victory in the 10-hour Road Atlanta marathonSant’Agata Bolognese/Braselton, GA, 12 October 2025 – The Lamborghini SC63…

4 weeks ago

Idorsia successfully completes an upsized offering of shares funding the company to overall profitability

Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, ITALY,…

4 weeks ago

Farizon SV shortlisted for International Van of the Year

Expert jurors from 26 countries select Farizon SV for IVOTY shortlist High standards of efficiency and safety are key factors…

4 weeks ago

UST Earns Three CandE Awards for Candidate Experience Excellence in North America, EMEA, and APAC

Prestigious recognition includes number one overall rank for the EMEA region  BENGALURU, India, Oct. 3, 2025 /PRNewswire/ -- UST, a…

1 month ago

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer…

1 month ago